Literature DB >> 1571536

Tyrosine phosphorylation of rasGAP and associated proteins in chronic myelogenous leukemia cell lines.

B Druker1, K Okuda, U Matulonis, R Salgia, T Roberts, J D Griffin.   

Abstract

The Philadelphia chromosome (Ph1), detected in virtually all cases of chronic myelogenous leukemia, is formed by a reciprocal translocation between chromosomes 9 and 22 that fuses BCR encoded sequences upstream of exon 2 of c-ABL. This oncogene produces a fusion protein (p210BCR/ABL) in which the ABL tyrosine kinase activity is elevated. This elevated kinase activity is essential for transformation, but the mechanisms involved are unknown. We report here that p21ras GTPase activating protein (rasGAP) or rasGAP-associated proteins p190 and p62 are phosphorylated on tyrosine in Ph1 (+) cell lines. Further, rasGAP coimmunoprecipitates with p210BCR/ABL in these cell lines. These results suggest that rasGAP or associated proteins are potential substrates for p210BCR/ABL kinase and thus directly link p210BCR/ABL with a signal transduction pathway known to be activated by hematopoietic growth factors (p21ras).

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1571536

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  19 in total

1.  CDNA microarray analysis of chronic myeloid leukemia.

Authors:  Huiyu Li; Shenghua Jie; Ping Zou; Guolin Zou
Journal:  Int J Hematol       Date:  2002-05       Impact factor: 2.490

2.  A chimeric receptor/oncogene that can be regulated by a ligand in vitro and in vivo.

Authors:  K Okuda; A D'Andrea; R A Etten; J D Griffin
Journal:  J Clin Invest       Date:  1997-10-01       Impact factor: 14.808

3.  Differential regulation of the p70 S6 kinase pathway by interferon alpha (IFNalpha) and imatinib mesylate (STI571) in chronic myelogenous leukemia cells.

Authors:  Simrit Parmar; Jessica Smith; Antonella Sassano; Shahab Uddin; Efstratios Katsoulidis; Beata Majchrzak; Suman Kambhampati; Elizabeth A Eklund; Martin S Tallman; Eleanor N Fish; Leonidas C Platanias
Journal:  Blood       Date:  2005-03-24       Impact factor: 22.113

4.  Association of p62, a multifunctional SH2- and SH3-domain-binding protein, with src family tyrosine kinases, Grb2, and phospholipase C gamma-1.

Authors:  S Richard; D Yu; K J Blumer; D Hausladen; M W Olszowy; P A Connelly; A S Shaw
Journal:  Mol Cell Biol       Date:  1995-01       Impact factor: 4.272

5.  Changes in tyrosine-phosphorylated p190 and its association with p120 type I and p100 type II rasGAPs during myelomonocytic differentiation of human leukemic cells.

Authors:  J C Cheng; A R Frackelton; E L Bearer; P S Kumar; B Kannan; A Santos-Moore; A Rifai; J Settleman; J W Clark
Journal:  Cell Growth Differ       Date:  1995-02

6.  Suppression of interferon (IFN)-inducible genes and IFN-mediated functional responses in BCR-ABL-expressing cells.

Authors:  Efstratios Katsoulidis; Antonella Sassano; Beata Majchrzak-Kita; Nathalie Carayol; Patrick Yoon; Alison Jordan; Brian J Druker; Eleanor N Fish; Leonidas C Platanias
Journal:  J Biol Chem       Date:  2008-02-20       Impact factor: 5.157

7.  Adenine causes cell cycle arrest and autophagy of chronic myelogenous leukemia K562 cells via AMP-activated protein kinase signaling.

Authors:  San-Yuan Chen; Chun-Hsiang Lin; Jiun-Tsai Lin; Yi-Fang Cheng; Han-Min Chen; Shao-Hsuan Kao
Journal:  Oncol Lett       Date:  2017-09-06       Impact factor: 2.967

8.  The TEL/ARG leukemia oncogene promotes viability and hyperresponsiveness to hematopoietic growth factors.

Authors:  Keiko Okuda; Yuko Sato; Yoshiaki Sonoda; James D Griffin
Journal:  Int J Hematol       Date:  2004-02       Impact factor: 2.490

Review 9.  Biology of chronic myeloid leukemia and possible therapeutic approaches to imatinib-resistant disease.

Authors:  Chikashi Yoshida; Junia V Melo
Journal:  Int J Hematol       Date:  2004-06       Impact factor: 2.490

10.  Ras complements the carboxyl terminus of v-Abl protein in lymphoid transformation.

Authors:  K Parmar; N Rosenberg
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.